While the understanding of the genomic aberrations that underpin chronic and acute myeloid leukaemia (CML and AML) has allowed the development of therapies for these diseases, limitations remain. These become apparent when looking at the frequency of treatment resistance leading to disease relapse in leukaemia patients. Key questions regarding the fundamental biology of the leukaemic cells, such as their metabolic dependencies, are still unresolved. Even though a majority of leukaemic cells are killed during initial treatment, persistent leukaemic stem cells (LSCs) and therapy-resistant cells are still not eradicated with current treatments, due to various mechanisms that may contribute to therapy resistance, including cellular metabolic ad...
Despite the development of selective BCR‐ABL‐targeting tyrosine kinase inhibitors (TKIs) transformin...
Chronic myeloid leukaemia (CML) is myeloproliferative disease that arises due to the formation of th...
Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. T...
Despite the development of selective BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) transformin...
Cancer cells, including leukemic cells, can react to therapeutic treatment by altering their metabol...
Despite the development of selective BCR‐ABL‐targeting tyrosine kinase inhibitors (TKIs) transformin...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase inhibitors (TKIs)...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-ge...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloi...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
Despite the development of selective BCR‐ABL‐targeting tyrosine kinase inhibitors (TKIs) transformin...
Chronic myeloid leukaemia (CML) is myeloproliferative disease that arises due to the formation of th...
Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. T...
Despite the development of selective BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) transformin...
Cancer cells, including leukemic cells, can react to therapeutic treatment by altering their metabol...
Despite the development of selective BCR‐ABL‐targeting tyrosine kinase inhibitors (TKIs) transformin...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-gen...
Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase inhibitors (TKIs)...
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-ge...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
Chemoresistance often complicates the management of cancer, as noted in the instance of acute myeloi...
The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to disease rel...
Despite the development of selective BCR‐ABL‐targeting tyrosine kinase inhibitors (TKIs) transformin...
Chronic myeloid leukaemia (CML) is myeloproliferative disease that arises due to the formation of th...
Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. T...